Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood

J.A. Boucek; J Turner

doi:10.1089/cbr.2013.1490

Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood

J.A. Boucek, J Turner

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Purpose: To report a comparison of SPECT/CT technique with standard blood-based dosimetry methodology in a cohort of non-Hodgkin lymphoma (NHL) patients treated with 131I-rituximab anti-CD20 chimeric monoclonal antibody. Methodology: Red marrow uptake was measured directly using serial quantitative whole-body imaging in conjunction with SPECT/CT in a cohort of 23 patients undergoing routine 131I-rituximab radioimmunotherapy of NHL. Absorbed dose measurements were then compared with radiation doses calculated using standard peripheral blood counting methodology. Results: Activity clearance from whole body of 88.7 hours measured by imaging 131I- rituximab was significantly slower (p

Original language	English
Pages (from-to)	18-25
Journal	Cancer Biotherapy and Radiopharmaceuticals
Volume	29
Issue number	1
DOIs	https://doi.org/10.1089/cbr.2013.1490
Publication status	Published - 2014

Access to Document

10.1089/cbr.2013.1490

Cite this

@article{22ddec4d2b8d4412a1e1d3bf8181b07a,

title = "Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood",

abstract = "Purpose: To report a comparison of SPECT/CT technique with standard blood-based dosimetry methodology in a cohort of non-Hodgkin lymphoma (NHL) patients treated with 131I-rituximab anti-CD20 chimeric monoclonal antibody. Methodology: Red marrow uptake was measured directly using serial quantitative whole-body imaging in conjunction with SPECT/CT in a cohort of 23 patients undergoing routine 131I-rituximab radioimmunotherapy of NHL. Absorbed dose measurements were then compared with radiation doses calculated using standard peripheral blood counting methodology. Results: Activity clearance from whole body of 88.7 hours measured by imaging 131I- rituximab was significantly slower (p",

author = "J.A. Boucek and J Turner",

year = "2014",

doi = "10.1089/cbr.2013.1490",

language = "English",

volume = "29",

pages = "18--25",

journal = "Cancer Biotherapy and Radiopharmaceuticals",

issn = "1084-9785",

publisher = "Mary Ann Liebert Inc",

number = "1",

}

TY - JOUR

T1 - Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood

AU - Boucek, J.A.

AU - Turner, J

PY - 2014

Y1 - 2014

N2 - Purpose: To report a comparison of SPECT/CT technique with standard blood-based dosimetry methodology in a cohort of non-Hodgkin lymphoma (NHL) patients treated with 131I-rituximab anti-CD20 chimeric monoclonal antibody. Methodology: Red marrow uptake was measured directly using serial quantitative whole-body imaging in conjunction with SPECT/CT in a cohort of 23 patients undergoing routine 131I-rituximab radioimmunotherapy of NHL. Absorbed dose measurements were then compared with radiation doses calculated using standard peripheral blood counting methodology. Results: Activity clearance from whole body of 88.7 hours measured by imaging 131I- rituximab was significantly slower (p

AB - Purpose: To report a comparison of SPECT/CT technique with standard blood-based dosimetry methodology in a cohort of non-Hodgkin lymphoma (NHL) patients treated with 131I-rituximab anti-CD20 chimeric monoclonal antibody. Methodology: Red marrow uptake was measured directly using serial quantitative whole-body imaging in conjunction with SPECT/CT in a cohort of 23 patients undergoing routine 131I-rituximab radioimmunotherapy of NHL. Absorbed dose measurements were then compared with radiation doses calculated using standard peripheral blood counting methodology. Results: Activity clearance from whole body of 88.7 hours measured by imaging 131I- rituximab was significantly slower (p

U2 - 10.1089/cbr.2013.1490

DO - 10.1089/cbr.2013.1490

M3 - Article

C2 - 24134141

SN - 1084-9785

VL - 29

SP - 18

EP - 25

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

IS - 1

ER -

Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood

Abstract

Access to Document

Fingerprint

Cite this